Pacira BioSciences, Inc. (PCRX)
NASDAQ: PCRX · Real-Time Price · USD
23.15
-0.49 (-2.07%)
May 8, 2026, 4:00 PM EDT - Market closed
Pacira BioSciences Stock Forecast
Stock Price Forecast
The 5 analysts that cover Pacira BioSciences stock have a consensus rating of "Strong Buy" and an average price target of $29.4, which forecasts a 27.00% increase in the stock price over the next year. The lowest target is $24 and the highest is $38.
Price Target: $29.4 (+27.00%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Pacira BioSciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Buy | 1 | 1 | 1 | 0 | 0 | 0 |
| Hold | 2 | 2 | 2 | 1 | 1 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Hold Maintains $22 → $24 | Hold | Maintains | $22 → $24 | +3.67% | May 1, 2026 |
| Needham | Needham | Strong Buy Maintains $30 → $32 | Strong Buy | Maintains | $30 → $32 | +38.23% | May 1, 2026 |
| Barclays | Barclays | Hold Maintains $27 → $25 | Hold | Maintains | $27 → $25 | +7.99% | Mar 26, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $38 | Strong Buy | Reiterates | $38 | +64.15% | Jan 9, 2026 |
| Needham | Needham | Strong Buy Maintains $30 | Strong Buy | Maintains | $30 | +29.59% | Jan 9, 2026 |
Financial Forecast
Revenue This Year
776.45M
from 726.41M
Increased by 6.89%
Revenue Next Year
838.42M
from 776.45M
Increased by 7.98%
EPS This Year
2.83
from 0.16
Increased by 1,694.64%
EPS Next Year
3.60
from 2.83
Increased by 27.19%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 806.5M | 884.8M | ||||||
| Avg | 776.5M | 838.4M | ||||||
| Low | 736.0M | 777.1M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 11.0% | 14.0% | ||||||
| Avg | 6.9% | 8.0% | ||||||
| Low | 1.3% | 0.1% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | 3.13 | 4.21 | |||||
| Avg | 2.83 | 3.60 | |||||
| Low | 2.38 | 3.04 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | 1,882.5% | 48.7% | |||||
| Avg | 1,694.6% | 27.2% | |||||
| Low | 1,408.8% | 7.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.